In short
This article discusses the ongoing clinical trials of PLX038, also known as Peg-7-Ethyl-10-Hydroxycamptothecin, a novel drug being investigated for the treatment of advanced or metastatic triple-negative breast cancer. The TOPOLOGY study, a phase II clinical trial, aims to evaluate the efficacy and safety of PLX038 in patients who have limited treatment options for this aggressive form of breast cancer.
At a glance
- Drug Name
- PLX038 (Peg-7-Ethyl-10-Hydroxycamptothecin)
- Trial Name
- TOPOLOGY
- Trial Phase
- Phase II
- Target Condition
- Advanced or metastatic triple-negative breast cancer
- Primary Objective
- Evaluate efficacy of PLX038 on response rate
- Key Secondary Objectives
- Assess time to response, duration of response, progression-free survival, overall survival, and safety
- Administration
- Intravenous infusion
- Key Eligibility Criteria
- At least two prior chemotherapy regimens, measurable disease, adequate organ function
- Key Exclusion Criteria
- Recent major surgery, active brain metastases, certain severe illnesses
What is PLX038?
PLX038, also known as PEG-7-ETHYL-10-HYDROXYCAMPTOTHECIN or DFP-13318, is a new drug being studied for the treatment of advanced or metastatic triple-negative breast cancer. It is a chemical compound that comes in the form of a solution for intravenous infusion, which means it is given directly into the bloodstream through a vein.
Target Condition: Advanced or Metastatic Triple-Negative Breast Cancer
Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and HER2 protein. This makes it more difficult to treat because common treatments that target these receptors are not effective. When this cancer is advanced or metastatic, it means it has spread beyond the breast to other parts of the body.
How PLX038 Works
While the exact mechanism of action is not fully described in the provided information, PLX038 is being studied for its potential to effectively treat triple-negative breast cancer. It belongs to a class of drugs called camptothecin derivatives, which are known to interfere with the DNA replication process in cancer cells, potentially stopping their growth and spread.
Clinical Trial Details
The clinical trial for PLX038, named "TOPOLOGY," is a Phase II study designed to evaluate the efficacy and safety of the drug in patients with locally advanced or metastatic triple-negative breast cancer. The main objectives of the trial include:
- Assessing the response rate to PLX038
- Evaluating time to response, duration of response, progression-free survival, and overall survival
- Studying the tolerability and safety of PLX038
- Investigating the efficacy of PLX038 in specific biomarker subgroups
- Analyzing the pharmacokinetics and pharmacodynamics of PLX038
Eligibility Criteria
To participate in the clinical trial, patients must meet certain criteria. Some key inclusion criteria are:
- Confirmed diagnosis of locally advanced or metastatic triple-negative breast cancer
- Have received at least two prior chemotherapy regimens for advanced or metastatic breast cancer
- Have measurable disease according to specific criteria (RECIST version 1.1)
- Be in generally good health with adequate organ function
There are also several exclusion criteria, such as recent major surgery, certain other medical conditions, or pregnancy.
Potential Benefits
The potential benefits of PLX038 are being investigated in the clinical trial. Researchers hope to see:
- Tumor response (reduction in tumor size)
- Increased time before the cancer progresses
- Longer overall survival
- Effectiveness in patients with specific biomarkers
Safety and Side Effects
As with any new medication, the safety and side effects of PLX038 are being closely monitored in the clinical trial. The study will record all adverse events (side effects) and serious adverse events that occur during treatment. It's important to note that as this is an investigational drug, not all potential side effects may be known at this time.
Administration
PLX038 is administered intravenously (through a vein) in a healthcare setting. The maximum daily dose being studied is 1730 mg/m² (milligrams per square meter of body surface area), with a maximum total dose of 27680 mg/m² over a treatment period of up to 12 months.